Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 15/20 | 0.72 |
| ▸ | BCR | P11274 | 13/20 | 0.72 |
| ▸ | SRC | P12931 | 5/20 | 0.72 |
| ▸ | EGFR | P00533 | 3/20 | 0.72 |
| ▸ | PRKACA | P17612 | 1/20 | 0.72 |
| ▸ | PRKACG | P22612 | 1/20 | 0.72 |
| ▸ | PRKACB | P22694 | 1/20 | 0.72 |
| ▸ | PRKCA | P17252 | 6/20 | 0.62 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.62 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.61 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.61 |
| ▸ | PRKCG | P05129 | 1/20 | 0.61 |
| ▸ | PRKCB | P05771 | 1/20 | 0.61 |
| ▸ | LCK | P06239 | 1/20 | 0.61 |
| ▸ | PRKCH | P24723 | 1/20 | 0.61 |
| ▸ | PRKCI | P41743 | 1/20 | 0.61 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.61 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.61 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.61 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7469833 | 0.94 | ABL1 (0.81) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL7476769 | 0.84 | ABL1 (1.00) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL1465 | 0.84 | ABL1 (1.00) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL3868291 | 0.82 | ABL1 (0.76) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL2009 | 0.81 | ABL1 (0.74) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL1978735 | 0.81 | ABL1 (0.69) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL17782807 | 0.81 | ABL1 (0.77) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL12950548 | 0.80 | ABL1 (0.72) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL2392 | 0.80 | ABL1 (1.00) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL3860532 | 0.80 | ABL1 (0.83) | ABL1BCRSRCEGFRPRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150252019-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. | 2015-09-10 | — | — | US | disclosed |
| US-20150252019-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252019-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | ABL1 240/4885BCR 2482/4885SRC 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.